115.50 -0.31 (-0.27%)
Pre-market: 9:19AM EDT
|Bid||115.40 x 800|
|Ask||116.88 x 800|
|Day's range||113.95 - 116.28|
|52-week range||79.11 - 116.28|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||39.75|
|Earnings date||29 Jul 2021 - 02 Aug 2021|
|Forward dividend & yield||5.20 (4.49%)|
|Ex-dividend date||14 Apr 2021|
|1y target est||123.78|
Is (ABBV) Outperforming Other Medical Stocks This Year?
AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day.
Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE: ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. In fact, eight years ago, Abbott spun out its biopharmaceutical segment into a separate company to protect the parent from Humira's impending patent cliff.